MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia

MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) requires refined risk stratification tools to drive decisions concerning effective therapeutic strategies. Here, genome-wide screening was carried out for identifying miRNA molecules capable of predicting treatment outcome in AML patients based on the TCGA dataset. We id...

Full description

Bibliographic Details
Main Authors: Mingshan Niu, Ninghan Zhang, Rong Wang, Tingting Shao, Yuan Feng, Yangling Shen, Xuejiao Liu, Kai Zhao, Shengyun Zhu, Linyan Xu, Yao Yao, Kailin Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Oncology
Subjects:
miR-340
acute myeloid leukemia
clinical outcome
chemotherapy
allo-HCST
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01058/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01058/full

Similar Items